KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Short term Debt (2019 - 2020)

Nektar Therapeutics has reported Short term Debt over the past 5 years, most recently at $254.1 million for Q1 2020.

  • Quarterly results put Short term Debt at $254.1 million for Q1 2020, changed N/A from a year ago — trailing twelve months through Mar 2020 was $254.1 million (changed N/A YoY), and the annual figure for FY2019 was $252.9 million, changed.
  • Short term Debt for Q1 2020 was $254.1 million at Nektar Therapeutics, roughly flat from $252.9 million in the prior quarter.
  • Over the last five years, Short term Debt for NKTR hit a ceiling of $254.1 million in Q1 2020 and a floor of $252.9 million in Q4 2019.